Tracers / [177Lu]Lu-FAP-2286
[177Lu]Lu-FAP-2286
Also written as [Lu-177]Lu-FAP-2286; FAP-2286; Lu-177-FAP-2286
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- first-in-human
- Syntheses indexed
- 4
What it is
- Compound class
- FAP-binding cyclic peptide conjugate (FAP-2286)
- Target / mechanism
- Targets fibroblast activation protein (FAP) PMID 34168013
- Clinical application
- Peptide-targeted radionuclide therapy (PTRT) of advanced adenocarcinomas PMID 34168013
- Theranostic pair
- <a href="/tracers/ga68-fap2286/">ga68-fap2286</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 41599688 2026 Pharmaceuticals (Basel) |
| Manual synthesis | — | — | — | ≥ 93% | FAP-2286 | 37261473 2023 Eur J Nucl Med Mol Imaging 177Lu-labeling was performed at different conditions, depending on the ligand (Supplementary Table 1). |
| — | — | — | — | — | — | 36813980 2023 Eur J Nucl Med Mol Imaging |
| PiRoSyn Sykam | — | — | — | >98% | FAP-2286 | 34168013 2022 J Nucl Med Automated labeling was performed using a PiRoSyn synthesis module (Sykam) (19). |
Need this precursor?We can point you to suppliers for [177Lu]Lu-FAP-2286, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 10 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 37261473: 'cyclic peptide FAP-2286'. Stage set/updated at stage 23 from PMID 34168013: 'We present the first-in-humans results using 177Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT).'.